- Actelion reported strong revenues and earnings - important news from clinical development expected in 2H 2009
- Vertex reported strong data at EASL meeting - Telaprevir well on track to become a blockbuster
- Novo Nordisk received positive recommendation from EMEA for approval of Victoza in the European Union